Poly(allylamine)/tripolyphosphate nanocomplex coacervate as a NLRP3-dependent systemic adjuvant for vaccine development
Gastón RizzoiD, Rodrigo C. O. SanchesiD, Camila Chavero, Daiana S. Bianchi, Eugenia Apuzzo, Santiago E. HerreraiD, Maximiliano L. AgazziiD, M. Lorena CorteziD, Waldemar A. MarmisolléiD, Irene Angélica KeitelmaniD, Analia Silvina TrevaniiD, Sergio Costa OliveiraiD, Omar AzzaroniiD, Paola SmaldiniiD, Guillermo Horacio DocenaiD
Abstract
Nanotechnology plays a crucial role in vaccine development. It allows the design of functional nanoparticles (NPs) that can act both as antigen carriers and as adjuvants to enhance the immune response. The present study aims to evaluate complex coacervate-like NPs composed of poly(allylamine hydrochloride) (PAH) and tripolyphosphate (TPP) as a safe vehicle and adjuvant for systemic vaccines. We investigated the activation of different antigen-presenting cells (APCs) with NPs and their adjuvanticity in Balbc/c and different KO mice that were intraperitoneally immunized with NP-OVA. We found that NPs increased the expression of CD86 and MHCII and promoted the production and secretion of interleukin-1{beta} (IL-1{beta}) and IL-18 through the inflammasome NLRP3 when macrophages and dendritic cells were co-incubated with LPS and NPs. We evidenced an unconventional IL-1{beta} release through the autophagosome pathway. The inhibition of autophagy with 3-methyladenine reduced the LPS/NPs-induced IL-1{beta} secretion. Additionally, our findings showed that the systemic administration of mice with NP-OVA triggered a significant induction of serum OVA-specific IgG and IgG2a, an increased secretion of IFN-{gamma} by spleen cells, and high frequencies of LT CD4+IFN-{gamma}+ and LT CD8+IFN-{gamma}+. Our findings show that NPs promoted the inflammasome activation of innate cells with Th1-dependent adjuvant properties, making them valuable for formulating novel preventive or therapeutic vaccines for infectious and non-infectious diseases. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=193 HEIGHT=200 SRC="FIGDIR/small/601578v2_ufig1.gif" ALT="Figure 1"> View larger version (39K): org.highwire.dtl.DTLVardef@60d382org.highwire.dtl.DTLVardef@de17b2org.highwire.dtl.DTLVardef@e5aebeorg.highwire.dtl.DTLVardef@13347b0_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 18th percentile
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Inhalable Polymeric Nanoparticle Vaccine for Lysosome-targeting Co-delivery of Antigen and Adjuvant with Enhanced Immunoprotection
Chenxi Dai, Hanchen Zhang, … Dongsheng Zhou·Advanced MaterialsPeer-reviewed·Apr 20, 2026
- Adenovirus-α-defensin complexes induce NLRP3-associated maturation of human phagocytes via TLR4 engagement
K. Eichholz, H. T. Tran, … E. J. Kremer·bioRxiv·Oct 26, 2021
- Combinational adjuvants delivered by ink-jet potentiate naked mRNA vaccines for robust protection against infectious diseases
Nan Qiao, Junichi Ishikawa, … Satoshi Uchida·bioRxiv·Dec 27, 2025
- Nanoparticle-Conjugated TLR9 Agonists Improve the Potency, Durability, and Breadth of COVID-19 Vaccines
B. S. Ou, J. Baillet, … E. Appel·bioRxiv·Jan 2, 2023
- Engineering nanoparticle surface chemistry for antigen-presenting cell targeting improves specificity and safety of TLR3 agonist cancer immunotherapy
Victoria F. Gomerdinger, Cassandra Parada, … Paula Therese Hammond·bioRxiv·Jun 25, 2026
- Lipid nanoparticle composition for adjuvant formulation modulates disease after influenza virus infection in QIV vaccinated mice.
Sonia Jangra, Alexander Lamoot, … Michael Schotsaert·Frontiers in ImmunologyPeer-reviewed·Apr 22, 2024